In mice, immunotherapy clears more residual melanoma cells

The tumor had shrunk, but the danger was still there. In mice with transplanted melanoma cells, Cornell researchers used targeted cancer drugs, then confronted the resistant cells left behind when the treatment stopped working. Their experiment removed many more residual melanoma cells, though it did not completely cure the animals.

The key was timing. Targeted therapies block mutated cancer-causing proteins and initially shrink tumors; they also cause dead cancer cells to alert the immune system. Macrophages then recruit T cells and natural killer cells—immune cells that can destroy cancer cells. Once resistance develops, however, the macrophages stop releasing the proteins that draw those cells in.

The Cornell team used a compound developed at Purdue University to reactivate the macrophages. In the mouse experiment, it made them continue secreting the recruiting proteins, helping immune cells reach and kill more of the resistant melanoma cells. The compound itself is considered a research tool, not a viable treatment.

That distinction matters. Earlier attempts to combine targeted therapies and immunotherapies at the same time were no more effective than either treatment alone and caused high toxicity, according to Andrew C. White, the study's senior author. The Cornell researchers instead argue that the therapies may work better in a particular sequence, as the tumor and its surrounding environment change over time.

So what changes in practice? Not treatment for patients yet. The immediate result is a route toward a drug that could be administered when melanoma becomes resistant to targeted therapy, with the aim of clearing residual cells before they lead to more disease. The evidence currently comes from mice, and the compound still has to be developed into a functional therapy.